Beaufort T M, Proost J H, Houwertjes M C, Roggeveld J, Wierda J M
Research Group for Experimental Anesthesiology and Clinical Pharmacology, University of Groningen, The Netherlands.
Anesthesiology. 1999 Feb;90(2):477-83. doi: 10.1097/00000542-199902000-00023.
It is not known whether the lungs influence the early pharmacokinetics of muscle relaxants and, if they do, whether differences in pulmonary uptake contribute to the differences in potency and/or onset time among muscle relaxants. Because the lungs are uniquely positioned, receive the entire cardiac output, have a large capillary surface area, and can temporarily store various basic drugs, the authors determined whether substantial pulmonary first-pass uptake of muscle relaxants occurs.
In 14 pigs, rocuronium, vecuronium, Org 9487, Org 7617, or d-tubocurarine were administered simultaneously with indocyanin green within 1 s into the right ventricle, and then arterial blood was sampled every 1.2 s (in the first min). The tibialis muscle response was registered mechanomyographically.
The maximum block was 93% (68-100% [median and range]). Onset times ranged from 83 s (78-86 s) for rocuronium to 182 s (172-192 s) for d-tubocurarine. Fraction-versus-time outflow curves showed that the peak of muscle relaxants and indocyanin green occurred almost simultaneously. Pulmonary first-pass retention was negligible. The retention of muscle relaxants at 95% passage of indocyanin green was -9% (-31 to 18%). The difference in the mean transit time between muscle relaxant and indocyanin green was 1.0 (0.8 to 1.4), 0.2 (-0.8 to 0.3), 0.3 (0.2 to 0.4), 0.5 (0.2 to 1.3), and -2.2 s for rocuronium, vecuronium, Org 9487, Org 7617, and d-tubocurarine, respectively.
There is no substantial pulmonary first-pass uptake of rocuronium, vecuronium, Org 9487, Org 7617, or d-tubocurarine in pigs. Therefore, differences in pulmonary first-pass uptake do not contribute to the differences in potency and/or onset time among muscle relaxants.
尚不清楚肺是否会影响肌松药的早期药代动力学,若有影响,肺摄取差异是否会导致不同肌松药在效价和/或起效时间上存在差异。由于肺所处位置独特,接受全部心输出量,具有大的毛细血管表面积,且能暂时储存多种碱性药物,因此作者研究了肌松药是否存在显著的肺首过摄取。
对14头猪在1秒内将罗库溴铵、维库溴铵、Org 9487、Org 7617或d -筒箭毒碱与吲哚菁绿同时注入右心室,然后在第1分钟内每隔1.2秒采集动脉血样。通过肌动图记录胫前肌反应。
最大阻滞率为93%(68 - 100%[中位数和范围])。起效时间从罗库溴铵的83秒(78 - 86秒)到d -筒箭毒碱的182秒(172 - 192秒)不等。分数-时间流出曲线显示肌松药和吲哚菁绿的峰值几乎同时出现。肺首过保留可忽略不计。在吲哚菁绿95%通过时,肌松药的保留率为 - 9%(- 31%至18%)。罗库溴铵、维库溴铵、Org 9487、Org 7617和d -筒箭毒碱的肌松药与吲哚菁绿平均通过时间差异分别为1.0(0.8至1.4)、0.2(- 0.8至0.3)、0.3(0.2至0.4)、0.5(0.2至1.3)和 - 2.2秒。
猪体内罗库溴铵、维库溴铵、Org 9487、Org 7617或d -筒箭毒碱不存在显著的肺首过摄取。因此,肺首过摄取差异不会导致不同肌松药在效价和/或起效时间上存在差异。